NTRA Diagnostics · Genetic testing · Oncology · High growth · Thesis updated June 12, 2026

Signatera growth is outrunning the legal overhang

Q1 2026 revenue rose 38.8% to $696.6 million, driven by higher test volumes and better selling prices.
Oncology units processed reached about 258,900 in Q1 2026, up from about 167,700 a year ago.
Signatera added about 24,000 clinical oncology units sequentially in Q1, its largest increase yet.
The main bear point is about $349 million of patent verdicts that Natera is appealing.
The stock price already assumes a lot of success, so execution has to stay very strong.

01 Running thesis

Cancer testing is pulling the story

Natera started 2026 with strong growth. Q1 revenue was $696.6 million, up 38.8% from last year. Total tests processed rose to about 1,013,600, and oncology units processed rose to about 258,900 from about 167,700 a year earlier.

The bull case is Signatera. This test looks for tiny traces of cancer DNA after treatment, which doctors call molecular residual disease. Management said clinical oncology units reached 249,000 in Q1 and rose by about 24,000 from Q4, the biggest sequential increase the company has reported. That pace helped management raise 2026 revenue guidance by more than $120 million and lift gross margin guidance to 65% at the midpoint.

The next layer of the bull case is new use. Data in bladder, rectal, and breast cancer suggests that some MRD-negative patients may be able to avoid major surgery. If doctors and payers accept that use case, Signatera could become more central to cancer care, not only a monitoring tool.

The bear case is not mainly weak demand today. It is price, legal risk, and the chance that growth slows after a strong run. Natera still posted an $85.1 million net loss in Q1 2026, and the stock already prices in a lot of future success. The clearest single risk is about $349 million of adverse patent verdicts from Ravgen and Guardant Health that Natera is appealing.

May 2026→The Q1 2026 10-Q confirmed the strong start already described on the earnings call. It showed about 258,900 oncology units processed, up from about 167,700 a year earlier, with no new major risk added.

May 2026▲Q1 results showed faster Signatera adoption, about 24,000 sequential clinical oncology unit adds, and a revenue guidance raise of more than $120 million. Management also pointed to Japan as a new growth path for the second half of 2026.

Feb 2026▲The 2025 10-K reduced the near-term LDT regulatory threat after the FDA rule was vacated. It also made the patent verdict risk clearer, with about $349 million tied to Ravgen and Guardant Health.

Feb 2026▲Q4 2025 showed another record Signatera quarter and positive cash flow for 2025. The Foresight Diagnostics acquisition and Latitude submission added new tools to the oncology portfolio.

Nov 2025→The Q3 2025 10-Q confirmed the strong oncology unit growth already discussed on the earnings call. It did not add a new business model change or risk.

Nov 2025▲Q3 2025 raised the growth bar again, with more than 21,500 sequential MRD unit adds and a large full-year guidance increase. New bladder cancer evidence strengthened the Signatera case.

Aug 2025→The Q2 2025 10-Q matched the earlier earnings update and did not change the thesis. The main view stayed centered on Signatera growth and patent litigation risk.

Aug 2025▲Q2 2025 marked a major acceleration for Signatera, with nearly 20,000 sequential oncology test adds. Management raised full-year revenue guidance while keeping operating expense guidance flat.

02 Business model

Labs, insurers, and test volume

Natera makes money by selling diagnostic tests. Most tests are run in its CLIA-certified labs, mainly in Austin, Texas and San Carlos, California. The company bills clinics, lab partners, patients, drug companies, and insurance payers.

The key payers are insurers. Natera says most revenue comes from insurers with in-network contracts. That gives the company more predictable payment, but the contracted price is usually below the list price. Growth depends on more doctors ordering tests, more payer coverage, and better average selling prices.

Natera also runs Constellation, a cloud model for partner labs. In that setup, another lab does the wet lab work and uses Natera's software algorithms. Natera gets lower revenue per test, but it also avoids much of the processing cost.

The model scales well when volumes rise faster than sales and lab costs. That is what bulls see in Signatera. It can break if reimbursement weakens, if doctors do not keep ordering more tests, or if legal costs force a large cash payment.

03 Product portfolio

Pregnancy roots, cancer engine

Growth engine

Signatera

Signatera is Natera's personalized MRD test for cancer patients. It is the main growth engine, with Q1 2026 oncology units processed up sharply from last year.

Cash cow

Panorama

Panorama is Natera's non-invasive prenatal test, often called NIPT. It remains one of the main revenue products and helps fund the faster-growing oncology push.

Cash cow

Horizon

Horizon is a carrier screening test used in women's health. Along with Panorama, it forms the mature base of the business.

Option

Latitude

Latitude is a tissue-free MRD test for colorectal cancer. It could expand Natera's reach because it does not need a tumor tissue sample.

Option

Fetal Focus

Fetal Focus is a single-gene NIPT product that was expanded to 21 genes. Management says the launch is running ahead of expectations.

Steady

Prospera

Prospera tests for transplant rejection in kidney, heart, and lung patients. It gives Natera a smaller but useful organ health franchise.

Option

Constellation

Constellation licenses Natera's bioinformatics tools to other labs through the cloud. Revenue per test is lower, but so are processing costs.

04 Business segments

Mostly U.S. direct selling

U.S. direct sales force96%growing fast

U.S. lab distribution partners3%modest

International partners and sales1%flat

Natera reports one operating segment. For Q1 2026, the filing gives revenue by sales channel: 96% U.S. direct sales force, 3% U.S. lab distribution partners, and 1% international lab partners and other international sales.

05 Risk factors

What could go wrong

Patent verdict cash hit

High impact · Medium odds

Natera has adverse 2024 jury verdicts of $57 million from Ravgen and more than $292 million from Guardant Health. The total is about $349 million before any appeal outcome or other legal changes. This is not an operating issue, but it could still reduce cash and hurt investor confidence.

We watchAppeal rulings, settlement news, or changes to legal accruals tied to Ravgen and Guardant Health.

Signatera volume slows

High impact · Medium odds

The bull case depends on Signatera staying on a very fast adoption curve. Management reported about 24,000 sequential clinical oncology unit adds in Q1 2026 after record adds in prior quarters. If that pace drops, the market may question the long-term growth story.

We watchQuarterly clinical oncology units and whether sequential adds stay above the recent record pace.

Coverage and pricing disappoint

High impact · Medium odds

Natera needs payer coverage and good average selling prices to turn test volume into profit. MolDx decisions on expanded Signatera submissions could add upside, but delays or lower payment would cap the benefit. In-network contracts also bring predictability, but often at prices below list price.

We watchMolDx coverage decisions for expanded colorectal cancer, breast, lung, and other Signatera uses, plus management's average selling price comments.

Japan launch underwhelms

Medium impact · Medium odds

Management expects a broad Japan launch for Signatera in the second half of 2026. It says Japan could effectively double Signatera's annual colorectal cancer volume market opportunity. That upside depends on approval timing, reimbursement, local sales execution, and doctor adoption.

We watchPMDA approval timing, Japan reimbursement levels, and early post-launch test volumes.

Future LDT regulation returns

Medium impact · Low odds

A major near-term regulatory threat fell after a federal court vacated the FDA's LDT rule in March 2025 and the FDA later rescinded it. But Congress could still bring back a law such as the VALID Act. Since Natera's products are laboratory developed tests, a new framework could add costs or slow launches.

We watchNew federal LDT legislation, VALID Act movement, or FDA policy changes.

High expectations meet losses

Medium impact · Medium odds

Natera is growing quickly, but it still reported an $85.1 million net loss in Q1 2026 and an accumulated deficit of $2.9 billion. It also had $95.1 million of stock-based compensation in the quarter. If revenue growth or gross margin slips, investors may focus more on dilution, cash use, and valuation.

We watchNet loss, cash from operations, stock-based compensation, and any change in 2026 guidance.

06 Quick answers

In one breath

What does Natera do?

Natera sells DNA-based diagnostic tests. Its biggest areas are women's health, cancer monitoring, and organ transplant health.

Why is Signatera important to Natera stock?

Signatera is the main growth driver. It helps detect tiny traces of cancer DNA after treatment, and Q1 2026 oncology unit growth showed fast adoption.

What is the biggest risk for Natera?

The clearest single risk is the patent litigation overhang. Natera is appealing adverse verdicts tied to Ravgen and Guardant Health that total about $349 million.

Is Natera profitable?

Natera reported an $85.1 million net loss in Q1 2026. It did generate $40.2 million of cash from operating activities in the quarter, so the profit picture is improving but not settled.